Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Jeong Uk Lim

doi:10.4046/trd.2022.0081

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Jeong Uk Lim

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.

Original language	English
Pages (from-to)	14-22
Number of pages	9
Journal	Tuberculosis and Respiratory Diseases
Volume	86
Issue number	1
DOIs	https://doi.org/10.4046/trd.2022.0081
State	Published - Jan 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 The Korean Academy of Tuberculosis and Respiratory Diseases.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biomarkers
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Protein Kinase Inhibitors
Recurrence

Access to Document

10.4046/trd.2022.0081

Cite this

@article{28714a2fba764a5ea8d7158ea6bc64f3,

title = "Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse",

abstract = "A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15\% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.",

keywords = "Biomarkers, Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant, Protein Kinase Inhibitors, Recurrence",

author = "Lim, \{Jeong Uk\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 The Korean Academy of Tuberculosis and Respiratory Diseases.",

year = "2023",

month = jan,

doi = "10.4046/trd.2022.0081",

language = "English",

volume = "86",

pages = "14--22",

journal = "Tuberculosis and Respiratory Diseases",

issn = "1738-3536",

publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",

number = "1",

}

TY - JOUR

T1 - Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

AU - Lim, Jeong Uk

PY - 2023/1

Y1 - 2023/1

N2 - A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.

AB - A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.

KW - Biomarkers

KW - Carcinoma, Non-Small-Cell Lung

KW - Chemotherapy, Adjuvant

KW - Protein Kinase Inhibitors

KW - Recurrence

UR - https://www.scopus.com/pages/publications/85159315696

U2 - 10.4046/trd.2022.0081

DO - 10.4046/trd.2022.0081

M3 - Review article

AN - SCOPUS:85159315696

SN - 1738-3536

VL - 86

SP - 14

EP - 22

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

IS - 1

ER -

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this